Sarita Kapila
Stock Analyst at Morgan Stanley
(0.89)
# 3,670
Out of 4,334 analysts
53
Total ratings
43.8%
Success rate
-4%
Average return
Main Sectors:
Stocks Rated by Sarita Kapila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Downgraded: Hold | $58 → $52 | $44.29 | +17.41% | 3 | May 1, 2026 | |
| SWX: ROP Roche Holding AG | Upgraded: Hold | $295 | $334.50 | -11.81% | 10 | Apr 24, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | $16,500 | $13,916.00 | +18.57% | 9 | Apr 13, 2026 | |
| RHHBY Roche Holding AG | Maintained: Sell | $39 → $46 | $53.34 | -13.76% | 2 | Apr 7, 2026 | |
| LON: 0NZT UCB SA | Downgraded: Hold | $260 | $242.15 | +7.37% | 6 | Mar 6, 2026 | |
| LON: GSK GSK plc | Maintained: Sell | $1,600 → $1,700 | $1,915.00 | -11.23% | 8 | Mar 2, 2026 | |
| EPA: SAN Sanofi | Upgraded: Buy | $100 | $77.46 | +29.10% | 1 | Sep 8, 2025 | |
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Maintained: Hold | $253 → $258 | $447.20 | n/a | 2 | May 4, 2023 | |
| GRFS Grifols | Maintained: Buy | $14 → $16 | $7.98 | n/a | 2 | Feb 8, 2023 | |
| BME: GRF Grifols, S.A. | Maintained: Buy | $14 → $16 | $9.70 | n/a | 6 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $235 | $50.26 | n/a | 4 | Nov 16, 2022 |
Sanofi
May 1, 2026
Downgraded: Hold
Price Target: $58 → $52
Current: $44.29
Upside: +17.41%
Roche Holding AG
Apr 24, 2026
Upgraded: Hold
Price Target: $295
Current: $334.50
Upside: -11.81%
AstraZeneca PLC
Apr 13, 2026
Maintained: Buy
Price Target: $16,500
Current: $13,916.00
Upside: +18.57%
Roche Holding AG
Apr 7, 2026
Maintained: Sell
Price Target: $39 → $46
Current: $53.34
Upside: -13.76%
UCB SA
Mar 6, 2026
Downgraded: Hold
Price Target: $260
Current: $242.15
Upside: +7.37%
GSK plc
Mar 2, 2026
Maintained: Sell
Price Target: $1,600 → $1,700
Current: $1,915.00
Upside: -11.23%
Sanofi
Sep 8, 2025
Upgraded: Buy
Price Target: $100
Current: $77.46
Upside: +29.10%
Swedish Orphan Biovitrum AB (publ)
May 4, 2023
Maintained: Hold
Price Target: $253 → $258
Current: $447.20
Upside: n/a
Grifols
Feb 8, 2023
Maintained: Buy
Price Target: $14 → $16
Current: $7.98
Upside: n/a
Grifols, S.A.
Feb 8, 2023
Maintained: Buy
Price Target: $14 → $16
Current: $9.70
Upside: n/a
Nov 16, 2022
Downgraded: Hold
Price Target: $235
Current: $50.26
Upside: n/a